A nested case-control study among patients with type 2 diabetes suggested that the use of SGLT-2i and other antidiabetic drug classes was not associated with an increased risk of fractures of the upper or lower limbs compared to use of DPP-4 inhibitors (Schmedt et al., 2019). This evidence concerns the gene DPP4 and type 2 diabetes mellitus.